About 65,958 results

Expert Perspective on ASCO20 Gastrointestinal Cancers Research

Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Donafenib Improves OS in Hepatocellular Carcinoma Compared With Sorafenib

May 28th, 2020 - Donafenib significantly improved overall survival (OS) rates compared with sorafenib in patients with hepatocellular carcinoma (HCC) and did so with favorable safety and tolerability, according to a new study (Abstract 4506).

Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients–Relationship to smoking and alcohol
JGH Open; Matsuura T

Oct 3rd, 2020 - The purpose of this study was to identify lifestyle risk factors, such as cigarette smoking and alcohol consumption, in relation to the development of hepatocellular carcinoma (HCC) among chronic hepatitis C patients who have achieved a sustained virologic response (SVR).

Hepatocellular carcinoma
Nature Reviews; Llovet JM

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis associated with metabolic syndrome or diabetes mel...

Hepatocellular Carcinoma - A Review
https://www.nejm.org/doi/10.1056/NEJMra1713263?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed
New England Journal of Medicine; Villanueva A

Apr 10th, 2019 - Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in the context of cirrhosis, hepatitis B or C virus infection, or nonalcoholic steatohepatitis. Underlying liver disease limits therapeutic efficacy.

Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options
Journal of Clinical and Translational Hepatology; Ghavimi S

Jun 27th, 2020 - With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise and has become the fifth most common cancer in men and the seventh most common cancer in women. Hepatocellular carcinoma (HCC) represents approximately 90% of all primary liver cancers and is a major global health concern. Patients with HCC can be managed curatively with surgical resection or with li...

Liver Cancer - StatPearls
StatPearls [Internet]; Recio-Boiles A

Nov 18th, 2020 - Hepatocellular carcinoma is the most common form of primary liver cancer in the United States with three-quarters of primary and secondary liver cancer cases. The trend for both estimated new and instances of death is increasing in parallel to the geographical underlying chronic liver disease or cirrhosis etiology. This activity reviews the causes, pathophysiology and presentation of liver canc...

Dietary factors can protect against liver cancer development
World Journal of Hepatology; Koumbi L

Jan 27th, 2017 - Liver cancer is the third leading cause of cancer mortality worldwide with hepatocellular carcinoma (HCC) representing more than 90% of primary liver cancers. Most HCC patients are also suffering from chronic liver disease (CLD). Evidence is emerging that the composition of diet plays an important role in HCC and CLD development and may also have a chemoprotective role.

Risk of hepatocellular carcinoma in relation to ABO blood type
Digestive and Liver Disease; Iavarone M

Jan 1st, 2016 - Mortality and incidence rates of hepatocellular carcinoma (HCC) parallel the geographical distribution of hepatitis B and C viruses among the general population, however genetic factors modulate individual cancer risk.

Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization
Therapeutics and Clinical Risk Management; Li Q

May 28th, 2018 - The association of ABO blood group with prognosis of several malignancies has been established. However, its role in hepatocellular carcinoma (HCC) remains unclear.

Diagnostic and Prognostic Implications of Cardiac Markers for Hepatocellular Carcinoma
Critical Reviews in Oncogenesis; Ghanta MK

Jan 1st, 2021 - Hepatocellular carcinoma (HC) is a malignant primary liver cancer which has poor treatment outcomes in advanced stages, and many of the HC patients present with advanced stages. The incidence of death due to HC increase as a result of ineffective treatments for advanced stage disease. Early diagnosis and management has proven benefits in both survival and quality of life. Currently very few bio...

Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes
Clinics in Geriatric Medicine; Mantovani A

Apr 16th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is common in older patients with type 2 diabetes. In older patients with type 2 diabetes, the presence of NAFLD is associated with a higher risk of hepatic (eg, nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma) and extrahepatic (eg, cardiovascular disease, sarcopenia, and dementia) complications than that observed in other patient gr...

Impacts of COVID-19 on Liver Cancers: During and after the Pandemic
Liver Cancer; Chan SL

Aug 31st, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) has diverted resources from healthcare services for patients with chronic medical illness such as cancer. COVID-19 also causes organ dysfunction, complicating cancer treatment. In most countries with an outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patie...

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
Singal,A.,et al

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

FDA approves ramucirumab for hepatocellular carcinoma

May 9th, 2019 - On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Zhu,A.,et al

Jan 17th, 2019 - Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson,A.,et al

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

Ramucirumab After Sorafenib in Patients With Advanced HCC and Increased α-Fetoprotein Concentrations

Jan 22nd, 2019 - The landscape of systemic therapy of hepatocellular carcinoma (HCC) has dramatically changed in the last 5 years with the introduction of various active agents into clinical pathways. The latest addition of agents with proof-of-efficacy in HCC is ramucirumab, an antibody against VEGF-R2. The published results of the REACH-2 trial in patients with prior sorafenib therapy demonstrate increased ov...

Hepatitis, Nonalcoholic Steatohepatitis
Sharma,B.,et al

Jan 31st, 2019 - Nonalcoholic, fatty liver disease (NAFLD) is defined as the ectopic accumulation of fat in the liver (hepatic steatosis) when no other causes of secondary, liver fat accumulation are present. As minor deposition of fat can occur in healthy adults, deposition of fat in at least 5% of hepatocytes is considered pathologic. Nonalcoholic steatohepatitis (NASH) is diagnosed via a liver biopsy when th...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
The American Journal of Gastroenterology; Kwo,P.,et al

Jun 30th, 2017 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with al...